Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Endocrinology
Volume 2013, Article ID 134241, 4 pages
Case Report

Successful Management of a Giant Pituitary Lactosomatotroph Adenoma Only with Cabergoline

1Department of Endocrinology and Metabolism Diseases, Faculty of Medicine, Baskent University, Turkey
2Department of Internal Medicine, Faculty of Medicine, Baskent University, Turkey

Received 13 March 2013; Accepted 20 April 2013

Academic Editors: M. A. Boyanov and T. Usui

Copyright © 2013 Emre Bozkirli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Although advances in endocrinologic and neuroradiologic research allow easier recognition of pituitary adenomas, giant pituitary tumours are relatively rare. In the literature, the term “giant” is generally used when a pituitary tumour becomes larger than 4 cm in diameter. Cabergoline is a potent and long-acting inhibitor of prolactin secretion, which exhibits high specificity and affinity for dopamine D2 receptor. Herein, we report a 46-year-old woman with a giant lactosomatotroph pituitary adenoma, sized  cm, who is treated successfully only with cabergoline. The patient showed dramatic response to cabergoline treatment by means of clinical, biochemical and radiological imaging findings. Cabergoline seems to be safe and effective in the treatment of prolactin and growth hormone cosecreting pituitary adenomas as well as prolactinomas. However, surgical or more aggressive approach must be considered where indicated.